| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aortic Aneurysm, Abdominal | 36 | 2021 | 236 | 5.310 |
Why?
|
| Blood Vessel Prosthesis Implantation | 34 | 2021 | 297 | 4.990 |
Why?
|
| Ischemia | 24 | 2019 | 199 | 4.710 |
Why?
|
| Vascular Surgical Procedures | 30 | 2018 | 251 | 4.290 |
Why?
|
| Endovascular Procedures | 20 | 2021 | 608 | 3.400 |
Why?
|
| Hypercholesterolemia | 6 | 2020 | 68 | 2.920 |
Why?
|
| Hindlimb | 18 | 2013 | 44 | 2.780 |
Why?
|
| Blood Vessel Prosthesis | 21 | 2021 | 215 | 2.030 |
Why?
|
| Peripheral Arterial Disease | 6 | 2019 | 163 | 2.020 |
Why?
|
| Stents | 25 | 2021 | 461 | 1.920 |
Why?
|
| Oxidative Stress | 9 | 2018 | 279 | 1.660 |
Why?
|
| Aortic Rupture | 7 | 2016 | 54 | 1.650 |
Why?
|
| Muscle, Skeletal | 16 | 2018 | 674 | 1.650 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2020 | 276 | 1.640 |
Why?
|
| Aortic Diseases | 9 | 2017 | 72 | 1.610 |
Why?
|
| Neovascularization, Physiologic | 9 | 2018 | 101 | 1.580 |
Why?
|
| Nitric Oxide Synthase Type III | 8 | 2012 | 21 | 1.560 |
Why?
|
| Aneurysm | 9 | 2019 | 56 | 1.540 |
Why?
|
| Time Factors | 41 | 2021 | 3615 | 1.490 |
Why?
|
| Aortic Aneurysm, Thoracic | 9 | 2021 | 105 | 1.470 |
Why?
|
| Arterial Occlusive Diseases | 10 | 2016 | 71 | 1.390 |
Why?
|
| Education, Medical, Graduate | 6 | 2018 | 317 | 1.340 |
Why?
|
| Peripheral Vascular Diseases | 7 | 2013 | 47 | 1.330 |
Why?
|
| Models, Cardiovascular | 4 | 2017 | 76 | 1.290 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2020 | 318 | 1.250 |
Why?
|
| Nitric Oxide | 5 | 2018 | 146 | 1.240 |
Why?
|
| Regional Blood Flow | 12 | 2018 | 108 | 1.230 |
Why?
|
| Treatment Outcome | 42 | 2021 | 5284 | 1.190 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2018 | 635 | 1.180 |
Why?
|
| Intermittent Claudication | 2 | 2019 | 53 | 1.180 |
Why?
|
| Clinical Competence | 10 | 2017 | 682 | 1.180 |
Why?
|
| Limb Salvage | 4 | 2017 | 69 | 1.150 |
Why?
|
| Internship and Residency | 6 | 2018 | 746 | 1.140 |
Why?
|
| Computer Simulation | 3 | 2017 | 458 | 1.110 |
Why?
|
| Wound Healing | 4 | 2018 | 174 | 1.100 |
Why?
|
| Endothelium, Vascular | 15 | 2011 | 169 | 1.080 |
Why?
|
| Postoperative Complications | 22 | 2021 | 1204 | 1.070 |
Why?
|
| Femoral Artery | 12 | 2008 | 101 | 1.060 |
Why?
|
| Male | 100 | 2021 | 27751 | 1.050 |
Why?
|
| Thrombosis | 3 | 2019 | 182 | 1.000 |
Why?
|
| Adenoviridae | 8 | 2010 | 117 | 0.980 |
Why?
|
| Lipoproteins, LDL | 3 | 2016 | 45 | 0.960 |
Why?
|
| Computer-Assisted Instruction | 2 | 2017 | 77 | 0.930 |
Why?
|
| Humans | 137 | 2021 | 59387 | 0.920 |
Why?
|
| Vascular Grafting | 3 | 2019 | 39 | 0.850 |
Why?
|
| Genetic Vectors | 13 | 2017 | 808 | 0.830 |
Why?
|
| Angioplasty | 8 | 2010 | 51 | 0.820 |
Why?
|
| Animals | 49 | 2020 | 19651 | 0.810 |
Why?
|
| Aged | 66 | 2021 | 13415 | 0.810 |
Why?
|
| Risk Factors | 30 | 2021 | 4986 | 0.800 |
Why?
|
| Quality Indicators, Health Care | 6 | 2016 | 332 | 0.790 |
Why?
|
| Venous Thrombosis | 5 | 2016 | 110 | 0.790 |
Why?
|
| Ascorbic Acid | 2 | 2012 | 46 | 0.790 |
Why?
|
| Female | 78 | 2021 | 30728 | 0.780 |
Why?
|
| Iliac Artery | 13 | 2021 | 49 | 0.770 |
Why?
|
| Aged, 80 and over | 37 | 2021 | 5124 | 0.770 |
Why?
|
| Disease Models, Animal | 10 | 2020 | 2053 | 0.770 |
Why?
|
| Hospital Mortality | 10 | 2016 | 841 | 0.760 |
Why?
|
| Arginine | 2 | 2012 | 110 | 0.760 |
Why?
|
| Decision Support Techniques | 2 | 2014 | 180 | 0.750 |
Why?
|
| Endarterectomy, Carotid | 9 | 2015 | 91 | 0.750 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2021 | 396 | 0.740 |
Why?
|
| Lower Extremity | 5 | 2014 | 152 | 0.710 |
Why?
|
| Rats | 17 | 2012 | 1910 | 0.710 |
Why?
|
| Endothelial Cells | 3 | 2013 | 173 | 0.700 |
Why?
|
| Surgeons | 3 | 2018 | 161 | 0.690 |
Why?
|
| Rats, Sprague-Dawley | 12 | 2012 | 574 | 0.680 |
Why?
|
| Gene Transfer Techniques | 8 | 2009 | 303 | 0.660 |
Why?
|
| Popliteal Artery | 1 | 2019 | 26 | 0.650 |
Why?
|
| Stem Cells | 3 | 2010 | 255 | 0.650 |
Why?
|
| Aorta | 5 | 2017 | 108 | 0.640 |
Why?
|
| Databases, Factual | 12 | 2021 | 814 | 0.620 |
Why?
|
| Prosthesis Design | 13 | 2021 | 209 | 0.620 |
Why?
|
| Phenotype | 6 | 2020 | 1137 | 0.610 |
Why?
|
| Renal Artery | 7 | 2021 | 31 | 0.600 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2016 | 127 | 0.600 |
Why?
|
| Apoptosis | 2 | 2016 | 1032 | 0.590 |
Why?
|
| Cell Differentiation | 4 | 2018 | 1304 | 0.580 |
Why?
|
| Coronary Vasospasm | 1 | 2017 | 11 | 0.580 |
Why?
|
| Collateral Circulation | 5 | 2018 | 22 | 0.570 |
Why?
|
| Genetic Therapy | 8 | 2017 | 733 | 0.570 |
Why?
|
| Rare Diseases | 1 | 2017 | 38 | 0.570 |
Why?
|
| Mixed Function Oxygenases | 1 | 2017 | 19 | 0.550 |
Why?
|
| Embolism | 2 | 2016 | 39 | 0.550 |
Why?
|
| Mice | 18 | 2020 | 10295 | 0.550 |
Why?
|
| Wound Infection | 1 | 2017 | 26 | 0.550 |
Why?
|
| Foot | 1 | 2017 | 41 | 0.540 |
Why?
|
| Reoperation | 11 | 2018 | 272 | 0.540 |
Why?
|
| Self-Assessment | 1 | 2017 | 58 | 0.540 |
Why?
|
| Fibromuscular Dysplasia | 3 | 2009 | 5 | 0.540 |
Why?
|
| Carotid Stenosis | 7 | 2015 | 104 | 0.540 |
Why?
|
| Recovery of Function | 5 | 2012 | 270 | 0.530 |
Why?
|
| Gene Expression | 7 | 2017 | 809 | 0.530 |
Why?
|
| Chi-Square Distribution | 9 | 2016 | 409 | 0.520 |
Why?
|
| Endothelial Progenitor Cells | 1 | 2016 | 8 | 0.520 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2013 | 37 | 0.510 |
Why?
|
| Antioxidants | 3 | 2014 | 241 | 0.510 |
Why?
|
| Vena Cava Filters | 1 | 2016 | 23 | 0.510 |
Why?
|
| Fibronectins | 2 | 2015 | 43 | 0.510 |
Why?
|
| Risk Assessment | 16 | 2021 | 1925 | 0.500 |
Why?
|
| Pulmonary Embolism | 2 | 2016 | 169 | 0.500 |
Why?
|
| Macrophages | 4 | 2018 | 1015 | 0.500 |
Why?
|
| Device Removal | 1 | 2016 | 64 | 0.490 |
Why?
|
| Fellowships and Scholarships | 2 | 2009 | 98 | 0.490 |
Why?
|
| Stroke | 6 | 2015 | 1127 | 0.490 |
Why?
|
| Blood Flow Velocity | 6 | 2008 | 68 | 0.480 |
Why?
|
| Hypertension | 4 | 2017 | 568 | 0.480 |
Why?
|
| Transduction, Genetic | 9 | 2003 | 228 | 0.480 |
Why?
|
| Practice Management, Medical | 1 | 2015 | 21 | 0.470 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 172 | 0.470 |
Why?
|
| Mice, Knockout | 7 | 2020 | 1997 | 0.460 |
Why?
|
| Carotid Artery Diseases | 4 | 2010 | 63 | 0.460 |
Why?
|
| Retrospective Studies | 27 | 2021 | 6072 | 0.460 |
Why?
|
| Acute Disease | 7 | 2019 | 658 | 0.460 |
Why?
|
| Inpatients | 3 | 2014 | 291 | 0.460 |
Why?
|
| Gene Deletion | 1 | 2015 | 293 | 0.450 |
Why?
|
| Middle Aged | 52 | 2021 | 16320 | 0.450 |
Why?
|
| Multivariate Analysis | 8 | 2017 | 902 | 0.450 |
Why?
|
| Aging | 1 | 2020 | 710 | 0.450 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 246 | 0.450 |
Why?
|
| MicroRNAs | 2 | 2018 | 616 | 0.450 |
Why?
|
| Anastomosis, Surgical | 4 | 2012 | 107 | 0.450 |
Why?
|
| Health Care Sector | 2 | 2015 | 20 | 0.440 |
Why?
|
| Aorta, Abdominal | 10 | 2021 | 58 | 0.440 |
Why?
|
| Aneurysm, Ruptured | 2 | 2015 | 71 | 0.440 |
Why?
|
| NADPH Oxidases | 2 | 2012 | 67 | 0.440 |
Why?
|
| Cellular Senescence | 2 | 2014 | 104 | 0.440 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 263 | 0.440 |
Why?
|
| Mice, Inbred C57BL | 9 | 2018 | 3231 | 0.440 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1151 | 0.430 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2016 | 188 | 0.430 |
Why?
|
| Radiography, Interventional | 3 | 2009 | 72 | 0.420 |
Why?
|
| Vascular Patency | 8 | 2021 | 135 | 0.420 |
Why?
|
| Oxygen | 4 | 2003 | 313 | 0.410 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2013 | 38 | 0.410 |
Why?
|
| Nitric Oxide Synthase | 2 | 2003 | 45 | 0.410 |
Why?
|
| Health Resources | 2 | 2010 | 88 | 0.410 |
Why?
|
| Aortography | 7 | 2017 | 55 | 0.410 |
Why?
|
| Aortic Aneurysm | 6 | 2019 | 81 | 0.410 |
Why?
|
| Apolipoproteins E | 4 | 2016 | 108 | 0.400 |
Why?
|
| Graft Occlusion, Vascular | 4 | 2021 | 62 | 0.400 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2017 | 725 | 0.400 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2012 | 190 | 0.400 |
Why?
|
| Problem-Based Learning | 1 | 2012 | 34 | 0.400 |
Why?
|
| Health Status Indicators | 1 | 2012 | 93 | 0.400 |
Why?
|
| Atherosclerosis | 2 | 2011 | 146 | 0.390 |
Why?
|
| Teaching | 1 | 2013 | 152 | 0.390 |
Why?
|
| Arteries | 5 | 2009 | 76 | 0.390 |
Why?
|
| Thoracic Outlet Syndrome | 4 | 2004 | 5 | 0.380 |
Why?
|
| Program Evaluation | 6 | 2018 | 470 | 0.380 |
Why?
|
| Celiac Artery | 4 | 1997 | 14 | 0.370 |
Why?
|
| Renal Artery Obstruction | 5 | 2002 | 18 | 0.370 |
Why?
|
| Faculty, Medical | 1 | 2013 | 192 | 0.370 |
Why?
|
| Laparotomy | 1 | 2010 | 47 | 0.350 |
Why?
|
| Adipocytes | 1 | 2012 | 255 | 0.350 |
Why?
|
| Patient Selection | 7 | 2016 | 465 | 0.340 |
Why?
|
| Carotid Arteries | 7 | 2015 | 62 | 0.340 |
Why?
|
| United States | 20 | 2018 | 7425 | 0.330 |
Why?
|
| Regenerative Medicine | 1 | 2009 | 19 | 0.330 |
Why?
|
| Splenic Artery | 3 | 2005 | 8 | 0.330 |
Why?
|
| Subclavian Vein | 3 | 2004 | 11 | 0.330 |
Why?
|
| Cardiology Service, Hospital | 1 | 2009 | 16 | 0.330 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 170 | 0.320 |
Why?
|
| Proportional Hazards Models | 5 | 2017 | 674 | 0.320 |
Why?
|
| Transgenes | 3 | 2017 | 177 | 0.320 |
Why?
|
| Personnel Selection | 1 | 2009 | 50 | 0.320 |
Why?
|
| alpha 1-Antitrypsin | 3 | 2017 | 87 | 0.320 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 3 | 2017 | 62 | 0.320 |
Why?
|
| Vascular Diseases | 3 | 2002 | 75 | 0.310 |
Why?
|
| Obesity | 1 | 2017 | 1166 | 0.310 |
Why?
|
| Chemokine CXCL12 | 1 | 2008 | 17 | 0.310 |
Why?
|
| Comorbidity | 6 | 2017 | 1078 | 0.310 |
Why?
|
| Follow-Up Studies | 19 | 2017 | 2340 | 0.300 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 228 | 0.300 |
Why?
|
| RNA, Small Interfering | 2 | 2012 | 857 | 0.290 |
Why?
|
| Muscles | 4 | 2017 | 173 | 0.290 |
Why?
|
| Brachiocephalic Trunk | 4 | 2003 | 15 | 0.290 |
Why?
|
| Quantitative Trait Loci | 1 | 2008 | 70 | 0.290 |
Why?
|
| Odds Ratio | 9 | 2015 | 746 | 0.290 |
Why?
|
| Cells, Cultured | 12 | 2018 | 2093 | 0.280 |
Why?
|
| Prospective Studies | 14 | 2021 | 3067 | 0.280 |
Why?
|
| Endarterectomy | 5 | 2002 | 18 | 0.280 |
Why?
|
| RNA, Messenger | 3 | 2008 | 1465 | 0.270 |
Why?
|
| Extremities | 3 | 2002 | 44 | 0.270 |
Why?
|
| Registries | 5 | 2021 | 799 | 0.270 |
Why?
|
| Membrane Glycoproteins | 1 | 2010 | 661 | 0.270 |
Why?
|
| Hepatic Artery | 2 | 1997 | 20 | 0.270 |
Why?
|
| Inflammation | 2 | 2005 | 1099 | 0.270 |
Why?
|
| Signal Transduction | 4 | 2016 | 2905 | 0.260 |
Why?
|
| Ankle | 1 | 2006 | 22 | 0.260 |
Why?
|
| Retroviridae | 5 | 1997 | 69 | 0.260 |
Why?
|
| Clinical Coding | 2 | 2017 | 44 | 0.260 |
Why?
|
| Curriculum | 4 | 2017 | 558 | 0.260 |
Why?
|
| Computed Tomography Angiography | 2 | 2017 | 110 | 0.260 |
Why?
|
| Fee-for-Service Plans | 2 | 2017 | 66 | 0.260 |
Why?
|
| Severity of Illness Index | 6 | 2017 | 1479 | 0.260 |
Why?
|
| Adult | 26 | 2021 | 15687 | 0.260 |
Why?
|
| Capillaries | 4 | 2003 | 30 | 0.260 |
Why?
|
| United States Food and Drug Administration | 2 | 2017 | 85 | 0.250 |
Why?
|
| Models, Animal | 4 | 2010 | 221 | 0.250 |
Why?
|
| Receptor, Notch1 | 2 | 2018 | 61 | 0.250 |
Why?
|
| Immunohistochemistry | 6 | 2017 | 847 | 0.240 |
Why?
|
| Learning Curve | 2 | 2017 | 30 | 0.240 |
Why?
|
| Hospitals | 4 | 2014 | 377 | 0.240 |
Why?
|
| Health Surveys | 1 | 2006 | 298 | 0.240 |
Why?
|
| Dependovirus | 4 | 2017 | 652 | 0.240 |
Why?
|
| Duodenum | 3 | 2000 | 42 | 0.240 |
Why?
|
| Capsid | 3 | 2017 | 88 | 0.230 |
Why?
|
| Receptors, Chemokine | 1 | 2004 | 37 | 0.230 |
Why?
|
| NADPH Oxidase 2 | 2 | 2018 | 35 | 0.230 |
Why?
|
| Hospital Costs | 3 | 2017 | 119 | 0.230 |
Why?
|
| Chemokine CCL2 | 1 | 2004 | 54 | 0.230 |
Why?
|
| Task Performance and Analysis | 2 | 2017 | 122 | 0.230 |
Why?
|
| Splanchnic Circulation | 2 | 1996 | 16 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2009 | 605 | 0.230 |
Why?
|
| Monocytes | 4 | 2011 | 345 | 0.230 |
Why?
|
| Angiography | 9 | 2015 | 145 | 0.230 |
Why?
|
| Nanoparticles | 1 | 2010 | 493 | 0.220 |
Why?
|
| Chemotaxis | 3 | 2009 | 48 | 0.220 |
Why?
|
| Balloon Occlusion | 1 | 2003 | 8 | 0.220 |
Why?
|
| Disease Progression | 4 | 2015 | 1122 | 0.220 |
Why?
|
| Logistic Models | 7 | 2015 | 1234 | 0.220 |
Why?
|
| Radiography | 5 | 2009 | 517 | 0.210 |
Why?
|
| Leg | 3 | 2013 | 85 | 0.210 |
Why?
|
| Coronary Artery Disease | 1 | 2006 | 274 | 0.210 |
Why?
|
| Thrombocytopenia | 1 | 2003 | 45 | 0.210 |
Why?
|
| Endothelial Growth Factors | 1 | 2003 | 20 | 0.210 |
Why?
|
| Predictive Value of Tests | 4 | 2014 | 1027 | 0.210 |
Why?
|
| Lymphokines | 1 | 2003 | 65 | 0.210 |
Why?
|
| Heparin | 1 | 2003 | 111 | 0.210 |
Why?
|
| Veins | 2 | 2002 | 61 | 0.200 |
Why?
|
| Patient Care Team | 2 | 2016 | 327 | 0.200 |
Why?
|
| Health Planning | 1 | 2002 | 29 | 0.200 |
Why?
|
| Radiology, Interventional | 1 | 2002 | 28 | 0.200 |
Why?
|
| Drug Synergism | 2 | 2012 | 132 | 0.200 |
Why?
|
| Isoenzymes | 1 | 2002 | 136 | 0.200 |
Why?
|
| Educational Measurement | 2 | 2017 | 211 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2009 | 197 | 0.190 |
Why?
|
| Phosphorylation | 2 | 2016 | 884 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2005 | 1507 | 0.190 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 152 | 0.190 |
Why?
|
| Pregnancy, Ectopic | 1 | 2021 | 10 | 0.190 |
Why?
|
| Mesenteric Artery, Superior | 2 | 2001 | 14 | 0.190 |
Why?
|
| Hyperemia | 1 | 2001 | 13 | 0.190 |
Why?
|
| Transfection | 3 | 2010 | 675 | 0.190 |
Why?
|
| Surgical Wound Infection | 2 | 2014 | 110 | 0.180 |
Why?
|
| Administration, Oral | 2 | 2012 | 356 | 0.180 |
Why?
|
| Chronic Disease | 7 | 2008 | 717 | 0.180 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 1560 | 0.180 |
Why?
|
| Quality Improvement | 2 | 2016 | 417 | 0.180 |
Why?
|
| Cicatrix | 1 | 2021 | 59 | 0.180 |
Why?
|
| Massachusetts | 5 | 2017 | 2019 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 441 | 0.180 |
Why?
|
| Arteriosclerosis | 5 | 2000 | 30 | 0.180 |
Why?
|
| Vascular Fistula | 1 | 2000 | 8 | 0.170 |
Why?
|
| Enzyme Activation | 2 | 2012 | 359 | 0.170 |
Why?
|
| Intestinal Fistula | 1 | 2000 | 10 | 0.170 |
Why?
|
| Cesarean Section | 1 | 2021 | 95 | 0.170 |
Why?
|
| Portal Vein | 1 | 2000 | 38 | 0.170 |
Why?
|
| New England | 4 | 2014 | 267 | 0.170 |
Why?
|
| Saphenous Vein | 2 | 2019 | 47 | 0.170 |
Why?
|
| Vena Cava, Inferior | 1 | 2000 | 28 | 0.170 |
Why?
|
| Methylation | 1 | 2020 | 124 | 0.170 |
Why?
|
| Fasciotomy | 1 | 2019 | 8 | 0.160 |
Why?
|
| Ligation | 1 | 2019 | 33 | 0.160 |
Why?
|
| Survival Rate | 8 | 2021 | 802 | 0.160 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2000 | 77 | 0.160 |
Why?
|
| Recurrence | 6 | 2021 | 603 | 0.160 |
Why?
|
| Ultrasonography, Doppler, Duplex | 3 | 2015 | 49 | 0.160 |
Why?
|
| Thrombolytic Therapy | 4 | 2004 | 184 | 0.160 |
Why?
|
| Mesenteric Arteries | 4 | 1996 | 9 | 0.160 |
Why?
|
| Syndrome | 2 | 2017 | 170 | 0.160 |
Why?
|
| Thrombectomy | 2 | 2016 | 208 | 0.160 |
Why?
|
| Calcium | 2 | 2012 | 555 | 0.160 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2000 | 135 | 0.160 |
Why?
|
| Microscopy, Confocal | 2 | 2012 | 226 | 0.160 |
Why?
|
| Program Development | 2 | 2015 | 203 | 0.150 |
Why?
|
| Lac Operon | 2 | 1996 | 26 | 0.150 |
Why?
|
| Motor Activity | 1 | 2001 | 333 | 0.150 |
Why?
|
| Workload | 2 | 2009 | 118 | 0.150 |
Why?
|
| Minocycline | 1 | 2018 | 24 | 0.150 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2018 | 15 | 0.150 |
Why?
|
| Viral Proteins | 1 | 2000 | 253 | 0.150 |
Why?
|
| Pericytes | 1 | 2018 | 15 | 0.150 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 132 | 0.140 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2018 | 48 | 0.140 |
Why?
|
| Contracts | 1 | 2017 | 8 | 0.140 |
Why?
|
| Catheterization | 3 | 1998 | 111 | 0.140 |
Why?
|
| Negotiating | 1 | 2017 | 14 | 0.140 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1997 | 15 | 0.140 |
Why?
|
| Device Approval | 1 | 2017 | 13 | 0.140 |
Why?
|
| Superoxides | 3 | 2013 | 69 | 0.140 |
Why?
|
| Lidocaine | 1 | 1997 | 30 | 0.140 |
Why?
|
| Natural Killer T-Cells | 1 | 2017 | 27 | 0.140 |
Why?
|
| Lymphocyte Activation | 2 | 2017 | 743 | 0.140 |
Why?
|
| Needs Assessment | 1 | 2018 | 187 | 0.140 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 306 | 0.130 |
Why?
|
| Pulmonary Artery | 1 | 1997 | 88 | 0.130 |
Why?
|
| Histones | 1 | 2020 | 458 | 0.130 |
Why?
|
| Cadaver | 1 | 2017 | 110 | 0.130 |
Why?
|
| Myocardial Infarction | 4 | 2014 | 861 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 806 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 70 | 0.130 |
Why?
|
| Health Services Needs and Demand | 1 | 2018 | 203 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 178 | 0.130 |
Why?
|
| Embolectomy | 1 | 2016 | 15 | 0.130 |
Why?
|
| Iliac Aneurysm | 3 | 2003 | 11 | 0.130 |
Why?
|
| Gangrene | 2 | 2009 | 7 | 0.130 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1996 | 66 | 0.130 |
Why?
|
| Cell Division | 6 | 2003 | 443 | 0.130 |
Why?
|
| Pennsylvania | 1 | 2016 | 62 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 354 | 0.130 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2016 | 4 | 0.130 |
Why?
|
| Organic Chemicals | 1 | 1996 | 22 | 0.130 |
Why?
|
| Current Procedural Terminology | 1 | 2016 | 16 | 0.130 |
Why?
|
| Data Accuracy | 1 | 2016 | 28 | 0.130 |
Why?
|
| Relative Value Scales | 1 | 2016 | 16 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 2 | 2009 | 137 | 0.130 |
Why?
|
| Pulmonary Edema | 2 | 1992 | 28 | 0.130 |
Why?
|
| Survival Analysis | 5 | 2015 | 555 | 0.130 |
Why?
|
| Shock | 1 | 2016 | 31 | 0.130 |
Why?
|
| Hypertension, Renovascular | 2 | 1995 | 4 | 0.130 |
Why?
|
| North America | 1 | 2016 | 105 | 0.130 |
Why?
|
| Trans-Activators | 1 | 2018 | 300 | 0.130 |
Why?
|
| Health Services Administration | 1 | 2015 | 4 | 0.130 |
Why?
|
| DNA Methylation | 1 | 2018 | 271 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2017 | 118 | 0.130 |
Why?
|
| Physician's Role | 1 | 2017 | 120 | 0.130 |
Why?
|
| Mesenteric Vascular Occlusion | 2 | 1999 | 14 | 0.130 |
Why?
|
| Educational Status | 1 | 2017 | 264 | 0.130 |
Why?
|
| Schizophrenia | 1 | 2018 | 243 | 0.130 |
Why?
|
| Cell Lineage | 1 | 2017 | 259 | 0.130 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 100 | 0.120 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 275 | 0.120 |
Why?
|
| Health Status | 2 | 2017 | 425 | 0.120 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2017 | 207 | 0.120 |
Why?
|
| Aorta, Thoracic | 5 | 2003 | 81 | 0.120 |
Why?
|
| Ultrasonography | 7 | 2004 | 457 | 0.120 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2015 | 43 | 0.120 |
Why?
|
| Length of Stay | 4 | 2015 | 777 | 0.120 |
Why?
|
| Mice, Mutant Strains | 3 | 2018 | 297 | 0.120 |
Why?
|
| Antipsychotic Agents | 1 | 2018 | 292 | 0.120 |
Why?
|
| Receptors, Leptin | 2 | 2018 | 13 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 2016 | 133 | 0.120 |
Why?
|
| Alkaline Phosphatase | 3 | 2002 | 46 | 0.120 |
Why?
|
| Leadership | 1 | 2017 | 195 | 0.120 |
Why?
|
| Health Services | 1 | 2015 | 81 | 0.120 |
Why?
|
| Interinstitutional Relations | 1 | 2015 | 37 | 0.120 |
Why?
|
| Organizational Objectives | 1 | 2015 | 57 | 0.120 |
Why?
|
| Thoracic Surgery | 1 | 2015 | 68 | 0.120 |
Why?
|
| Microcirculation | 2 | 1994 | 52 | 0.110 |
Why?
|
| Models, Organizational | 1 | 2015 | 92 | 0.110 |
Why?
|
| Fluorescent Dyes | 1 | 1996 | 196 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2017 | 692 | 0.110 |
Why?
|
| Neutrophils | 1 | 2017 | 363 | 0.110 |
Why?
|
| Injections, Intramuscular | 3 | 2013 | 67 | 0.110 |
Why?
|
| Renal Dialysis | 1 | 2015 | 189 | 0.110 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 103 | 0.110 |
Why?
|
| Hospitals, Teaching | 2 | 2017 | 101 | 0.110 |
Why?
|
| Angioplasty, Balloon | 3 | 1995 | 57 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2014 | 29 | 0.110 |
Why?
|
| Telomere Shortening | 1 | 2014 | 8 | 0.110 |
Why?
|
| Chlamydophila Infections | 2 | 2005 | 6 | 0.110 |
Why?
|
| Prognosis | 6 | 2015 | 1600 | 0.110 |
Why?
|
| Popliteal Vein | 1 | 1993 | 2 | 0.110 |
Why?
|
| Medical Audit | 1 | 2014 | 58 | 0.110 |
Why?
|
| Chlamydophila pneumoniae | 2 | 2005 | 21 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 52 | 0.110 |
Why?
|
| Thrombophlebitis | 1 | 1993 | 16 | 0.110 |
Why?
|
| Health Care Surveys | 3 | 2009 | 277 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2014 | 51 | 0.110 |
Why?
|
| Femoral Vein | 1 | 1993 | 18 | 0.110 |
Why?
|
| Stress, Mechanical | 2 | 2009 | 110 | 0.110 |
Why?
|
| Artificial Limbs | 1 | 2013 | 4 | 0.110 |
Why?
|
| Prosthesis Fitting | 1 | 2013 | 7 | 0.110 |
Why?
|
| Medicare | 2 | 2016 | 601 | 0.110 |
Why?
|
| Iliac Vein | 1 | 1993 | 9 | 0.110 |
Why?
|
| Cardiology | 1 | 2015 | 163 | 0.110 |
Why?
|
| Mitochondrial Dynamics | 1 | 2013 | 5 | 0.110 |
Why?
|
| Hemodynamics | 3 | 2001 | 230 | 0.110 |
Why?
|
| Macrophage Activation | 2 | 1992 | 118 | 0.110 |
Why?
|
| Societies, Medical | 2 | 2009 | 337 | 0.110 |
Why?
|
| Cell Transdifferentiation | 1 | 2013 | 13 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 210 | 0.110 |
Why?
|
| Insulin | 2 | 2018 | 674 | 0.100 |
Why?
|
| NADPH Oxidase 4 | 1 | 2012 | 6 | 0.100 |
Why?
|
| Coronary Vessels | 4 | 1991 | 109 | 0.100 |
Why?
|
| Motor Skills | 1 | 2013 | 60 | 0.100 |
Why?
|
| Discriminant Analysis | 1 | 2012 | 17 | 0.100 |
Why?
|
| Multipotent Stem Cells | 1 | 2012 | 13 | 0.100 |
Why?
|
| Health Services Research | 1 | 2014 | 266 | 0.100 |
Why?
|
| Nitrites | 1 | 2012 | 8 | 0.100 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 1370 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 205 | 0.100 |
Why?
|
| C-Reactive Protein | 2 | 2005 | 159 | 0.100 |
Why?
|
| Nitrates | 1 | 2012 | 19 | 0.100 |
Why?
|
| Cell Proliferation | 2 | 2014 | 942 | 0.100 |
Why?
|
| Ion Channels | 1 | 2013 | 88 | 0.100 |
Why?
|
| Video Recording | 1 | 2013 | 126 | 0.100 |
Why?
|
| Phlebography | 2 | 2004 | 43 | 0.100 |
Why?
|
| Myocardial Ischemia | 1 | 2013 | 111 | 0.100 |
Why?
|
| Checklist | 1 | 2013 | 72 | 0.100 |
Why?
|
| Dogs | 9 | 1996 | 314 | 0.100 |
Why?
|
| Models, Anatomic | 1 | 2012 | 60 | 0.100 |
Why?
|
| Mitochondrial Proteins | 1 | 2013 | 100 | 0.100 |
Why?
|
| Receptors, Cell Surface | 3 | 2011 | 428 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2014 | 349 | 0.100 |
Why?
|
| Treatment Failure | 3 | 2015 | 185 | 0.100 |
Why?
|
| ROC Curve | 1 | 2012 | 267 | 0.100 |
Why?
|
| Cardiac Catheterization | 3 | 1991 | 253 | 0.100 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 1991 | 10 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 243 | 0.100 |
Why?
|
| Ornithine Decarboxylase | 2 | 1992 | 9 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 706 | 0.090 |
Why?
|
| Self Report | 1 | 2014 | 359 | 0.090 |
Why?
|
| Models, Biological | 2 | 2012 | 1143 | 0.090 |
Why?
|
| Aneurysm, False | 2 | 2003 | 46 | 0.090 |
Why?
|
| Necrosis | 1 | 2012 | 140 | 0.090 |
Why?
|
| Arterioles | 1 | 1991 | 7 | 0.090 |
Why?
|
| Vasodilation | 1 | 1991 | 35 | 0.090 |
Why?
|
| Constriction, Pathologic | 2 | 2004 | 112 | 0.090 |
Why?
|
| Radiographic Image Enhancement | 2 | 2002 | 97 | 0.090 |
Why?
|
| Decompression, Surgical | 2 | 2004 | 61 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2015 | 513 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 289 | 0.090 |
Why?
|
| In Vitro Techniques | 3 | 2002 | 471 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 3 | 2008 | 495 | 0.090 |
Why?
|
| Endoleak | 2 | 2021 | 39 | 0.090 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 192 | 0.090 |
Why?
|
| Adenosine | 1 | 1991 | 70 | 0.090 |
Why?
|
| Norepinephrine | 1 | 1991 | 98 | 0.090 |
Why?
|
| Cell Movement | 1 | 2012 | 429 | 0.090 |
Why?
|
| Regeneration | 1 | 1991 | 93 | 0.090 |
Why?
|
| Home Care Services | 2 | 2010 | 97 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2011 | 170 | 0.090 |
Why?
|
| Neointima | 1 | 2010 | 19 | 0.090 |
Why?
|
| Cerebrovascular Circulation | 1 | 1991 | 174 | 0.090 |
Why?
|
| Rats, Wistar | 3 | 1996 | 179 | 0.090 |
Why?
|
| Glutathione | 1 | 2010 | 54 | 0.090 |
Why?
|
| Hydrogen Peroxide | 1 | 2010 | 76 | 0.080 |
Why?
|
| Hyperplasia | 1 | 2010 | 84 | 0.080 |
Why?
|
| beta-Galactosidase | 3 | 2003 | 77 | 0.080 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 203 | 0.080 |
Why?
|
| Intraoperative Complications | 3 | 2021 | 85 | 0.080 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2009 | 10 | 0.080 |
Why?
|
| Reperfusion Injury | 1 | 1990 | 49 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 1992 | 206 | 0.080 |
Why?
|
| Skilled Nursing Facilities | 1 | 2010 | 83 | 0.080 |
Why?
|
| Toes | 1 | 2009 | 13 | 0.080 |
Why?
|
| Receptors, CXCR4 | 1 | 2009 | 34 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2009 | 20 | 0.080 |
Why?
|
| Patient Discharge | 2 | 2010 | 490 | 0.080 |
Why?
|
| Young Adult | 2 | 2017 | 4272 | 0.080 |
Why?
|
| Cell Adhesion | 4 | 1995 | 207 | 0.080 |
Why?
|
| Accreditation | 1 | 2009 | 73 | 0.080 |
Why?
|
| Tyrosine | 1 | 2009 | 92 | 0.080 |
Why?
|
| Iatrogenic Disease | 1 | 2009 | 58 | 0.080 |
Why?
|
| Peer Review, Research | 1 | 2009 | 46 | 0.080 |
Why?
|
| Microspheres | 4 | 2005 | 55 | 0.080 |
Why?
|
| Critical Illness | 2 | 2010 | 325 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 2516 | 0.080 |
Why?
|
| Brachial Artery | 2 | 2006 | 28 | 0.080 |
Why?
|
| Elective Surgical Procedures | 4 | 2014 | 112 | 0.080 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2008 | 6 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2010 | 584 | 0.080 |
Why?
|
| Specialties, Surgical | 1 | 2009 | 45 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2011 | 292 | 0.080 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2000 | 47 | 0.080 |
Why?
|
| Hypoxia | 1 | 2009 | 112 | 0.080 |
Why?
|
| Suture Techniques | 2 | 2000 | 91 | 0.080 |
Why?
|
| Blood Pressure | 3 | 2006 | 495 | 0.070 |
Why?
|
| Body Weight | 1 | 2009 | 368 | 0.070 |
Why?
|
| Coronary Circulation | 2 | 1985 | 50 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 349 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 527 | 0.070 |
Why?
|
| Aortic Valve | 2 | 1991 | 173 | 0.070 |
Why?
|
| Thromboembolism | 2 | 2002 | 69 | 0.070 |
Why?
|
| Incidence | 4 | 2015 | 1239 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2009 | 461 | 0.070 |
Why?
|
| Mutation | 2 | 2018 | 2456 | 0.070 |
Why?
|
| Wounds and Injuries | 1 | 2009 | 229 | 0.070 |
Why?
|
| Pressure | 3 | 2002 | 76 | 0.070 |
Why?
|
| Homocysteine | 1 | 2006 | 33 | 0.070 |
Why?
|
| Fibrinogen | 1 | 2006 | 31 | 0.070 |
Why?
|
| Age of Onset | 1 | 2006 | 170 | 0.060 |
Why?
|
| Pancreas | 2 | 1997 | 146 | 0.060 |
Why?
|
| Demography | 1 | 2006 | 169 | 0.060 |
Why?
|
| Injections, Intra-Arterial | 1 | 2005 | 20 | 0.060 |
Why?
|
| Algorithms | 1 | 2011 | 974 | 0.060 |
Why?
|
| Attitude of Health Personnel | 2 | 2017 | 551 | 0.060 |
Why?
|
| Nutrition Surveys | 1 | 2006 | 129 | 0.060 |
Why?
|
| Databases as Topic | 3 | 2010 | 52 | 0.060 |
Why?
|
| Cardiomegaly | 1 | 2005 | 29 | 0.060 |
Why?
|
| Random Allocation | 1 | 2005 | 192 | 0.060 |
Why?
|
| Arteriovenous Malformations | 1 | 2005 | 43 | 0.060 |
Why?
|
| Biomarkers | 3 | 2018 | 1306 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 297 | 0.060 |
Why?
|
| Intraoperative Period | 1 | 2004 | 33 | 0.060 |
Why?
|
| Preoperative Period | 2 | 2015 | 61 | 0.060 |
Why?
|
| Genetic Engineering | 1 | 2005 | 111 | 0.060 |
Why?
|
| Receptors, CCR2 | 1 | 2004 | 14 | 0.060 |
Why?
|
| Immunophenotyping | 2 | 2017 | 184 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2005 | 310 | 0.060 |
Why?
|
| Certification | 2 | 2018 | 46 | 0.060 |
Why?
|
| Prevalence | 2 | 2006 | 1252 | 0.060 |
Why?
|
| Biopsy | 2 | 2017 | 410 | 0.060 |
Why?
|
| Tissue Plasminogen Activator | 2 | 1996 | 125 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 1552 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 2 | 2011 | 85 | 0.050 |
Why?
|
| Hyperthyroidism | 1 | 2003 | 16 | 0.050 |
Why?
|
| Erectile Dysfunction | 1 | 2003 | 22 | 0.050 |
Why?
|
| Brain Infarction | 1 | 2003 | 19 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2003 | 19 | 0.050 |
Why?
|
| Upper Extremity | 1 | 2003 | 49 | 0.050 |
Why?
|
| Transplantation, Autologous | 3 | 2009 | 119 | 0.050 |
Why?
|
| GPI-Linked Proteins | 1 | 2002 | 39 | 0.050 |
Why?
|
| Humerus | 1 | 2002 | 9 | 0.050 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 2002 | 3 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2018 | 715 | 0.050 |
Why?
|
| Epidemiologic Methods | 1 | 2002 | 65 | 0.050 |
Why?
|
| Ulnar Artery | 1 | 2002 | 11 | 0.050 |
Why?
|
| Colon | 2 | 1996 | 136 | 0.050 |
Why?
|
| DNA Primers | 1 | 2003 | 289 | 0.050 |
Why?
|
| Blood Loss, Surgical | 1 | 2002 | 57 | 0.050 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2002 | 13 | 0.050 |
Why?
|
| Hemostatics | 1 | 2002 | 26 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2002 | 146 | 0.050 |
Why?
|
| Base Sequence | 2 | 2003 | 1302 | 0.050 |
Why?
|
| Viscera | 2 | 1999 | 10 | 0.050 |
Why?
|
| Aortic Valve Stenosis | 1 | 1984 | 170 | 0.050 |
Why?
|
| Radial Artery | 1 | 2002 | 49 | 0.050 |
Why?
|
| Physical Fitness | 1 | 1982 | 92 | 0.050 |
Why?
|
| Forecasting | 1 | 2002 | 220 | 0.050 |
Why?
|
| Embolization, Therapeutic | 2 | 2003 | 308 | 0.050 |
Why?
|
| Swine | 1 | 2002 | 352 | 0.050 |
Why?
|
| Skin | 2 | 2005 | 357 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 1996 | 588 | 0.050 |
Why?
|
| Paraplegia | 1 | 2001 | 5 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2003 | 931 | 0.050 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2021 | 39 | 0.050 |
Why?
|
| Groin | 1 | 2001 | 14 | 0.050 |
Why?
|
| Paraparesis | 1 | 2021 | 9 | 0.050 |
Why?
|
| Organ Size | 1 | 2001 | 164 | 0.050 |
Why?
|
| Heart Diseases | 1 | 2003 | 206 | 0.040 |
Why?
|
| Mesocricetus | 2 | 1991 | 93 | 0.040 |
Why?
|
| Paraganglioma | 1 | 2000 | 2 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2000 | 13 | 0.040 |
Why?
|
| Duodenoscopy | 1 | 2000 | 3 | 0.040 |
Why?
|
| Portography | 1 | 2000 | 2 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2002 | 525 | 0.040 |
Why?
|
| Chromosome Deletion | 1 | 2000 | 41 | 0.040 |
Why?
|
| Simplexvirus | 1 | 2000 | 25 | 0.040 |
Why?
|
| Cricetinae | 2 | 1991 | 366 | 0.040 |
Why?
|
| Immediate-Early Proteins | 1 | 2000 | 44 | 0.040 |
Why?
|
| Emergencies | 2 | 2014 | 110 | 0.040 |
Why?
|
| Equipment Design | 1 | 2001 | 329 | 0.040 |
Why?
|
| Constriction | 1 | 1999 | 8 | 0.040 |
Why?
|
| Polytetrafluoroethylene | 2 | 1996 | 18 | 0.040 |
Why?
|
| Linear Models | 2 | 2015 | 403 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2000 | 148 | 0.040 |
Why?
|
| Creatinine | 1 | 1999 | 128 | 0.040 |
Why?
|
| Chorion | 1 | 1998 | 5 | 0.040 |
Why?
|
| Amniocentesis | 1 | 1998 | 5 | 0.040 |
Why?
|
| Amnion | 1 | 1998 | 9 | 0.040 |
Why?
|
| Surgical Instruments | 1 | 1999 | 41 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2013 | 365 | 0.040 |
Why?
|
| Interferon-gamma | 2 | 2011 | 551 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2000 | 289 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2000 | 377 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 2 | 1991 | 53 | 0.040 |
Why?
|
| Prosthesis-Related Infections | 1 | 1998 | 33 | 0.040 |
Why?
|
| Vascular Remodeling | 1 | 2018 | 24 | 0.040 |
Why?
|
| Schizophrenic Psychology | 1 | 2018 | 65 | 0.040 |
Why?
|
| Heart Failure | 2 | 2014 | 853 | 0.040 |
Why?
|
| Centrifugation | 1 | 1997 | 10 | 0.040 |
Why?
|
| Morbidity | 1 | 2017 | 113 | 0.040 |
Why?
|
| Competitive Bidding | 1 | 2017 | 4 | 0.040 |
Why?
|
| Centralized Hospital Services | 1 | 2017 | 5 | 0.030 |
Why?
|
| Hospital Charges | 1 | 2017 | 23 | 0.030 |
Why?
|
| Regional Health Planning | 1 | 2017 | 10 | 0.030 |
Why?
|
| Plethysmography, Impedance | 1 | 1977 | 3 | 0.030 |
Why?
|
| Cardiography, Impedance | 1 | 1977 | 4 | 0.030 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 17 | 0.030 |
Why?
|
| Fibrinolysin | 1 | 1996 | 5 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 1977 | 35 | 0.030 |
Why?
|
| Pregnancy | 2 | 2021 | 2213 | 0.030 |
Why?
|
| Genetic Markers | 1 | 1997 | 116 | 0.030 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 32 | 0.030 |
Why?
|
| Dinoprostone | 1 | 1996 | 44 | 0.030 |
Why?
|
| Virion | 1 | 1997 | 119 | 0.030 |
Why?
|
| Quality of Life | 1 | 2003 | 1137 | 0.030 |
Why?
|
| Inservice Training | 1 | 2017 | 81 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2009 | 206 | 0.030 |
Why?
|
| Postoperative Period | 2 | 2014 | 127 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 2017 | 95 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 1996 | 50 | 0.030 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2017 | 176 | 0.030 |
Why?
|
| Stomach | 1 | 1996 | 83 | 0.030 |
Why?
|
| Hospitals, Veterans | 2 | 2015 | 159 | 0.030 |
Why?
|
| Plasminogen Activators | 1 | 1995 | 10 | 0.030 |
Why?
|
| Benchmarking | 1 | 2017 | 135 | 0.030 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2015 | 7 | 0.030 |
Why?
|
| Health Expenditures | 1 | 2017 | 116 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 46 | 0.030 |
Why?
|
| Cell Line | 1 | 2000 | 1984 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 244 | 0.030 |
Why?
|
| Nadolol | 1 | 1995 | 4 | 0.030 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 1995 | 3 | 0.030 |
Why?
|
| Atenolol | 1 | 1995 | 9 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1996 | 446 | 0.030 |
Why?
|
| Propranolol | 1 | 1995 | 21 | 0.030 |
Why?
|
| Documentation | 1 | 2016 | 127 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 24 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2003 | 2052 | 0.030 |
Why?
|
| Blood | 2 | 1995 | 29 | 0.030 |
Why?
|
| Microinjections | 1 | 1994 | 67 | 0.030 |
Why?
|
| Recombinant Proteins | 3 | 1992 | 689 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 1996 | 644 | 0.030 |
Why?
|
| Gadolinium | 1 | 1995 | 103 | 0.030 |
Why?
|
| Cell Survival | 1 | 1996 | 559 | 0.030 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2013 | 4 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 1995 | 178 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 147 | 0.030 |
Why?
|
| Color | 1 | 1993 | 21 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 149 | 0.030 |
Why?
|
| Compression Bandages | 1 | 2013 | 2 | 0.030 |
Why?
|
| Early Ambulation | 1 | 2013 | 6 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 2014 | 71 | 0.030 |
Why?
|
| Clone Cells | 1 | 2013 | 106 | 0.030 |
Why?
|
| Uncoupling Protein 2 | 1 | 2013 | 4 | 0.030 |
Why?
|
| Image Enhancement | 1 | 1995 | 188 | 0.030 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2013 | 14 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2013 | 23 | 0.030 |
Why?
|
| Cell Membrane | 1 | 1996 | 486 | 0.030 |
Why?
|
| Troponin | 1 | 2013 | 36 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2013 | 119 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 98 | 0.030 |
Why?
|
| Cattle | 1 | 2013 | 304 | 0.030 |
Why?
|
| Contrast Media | 1 | 1995 | 400 | 0.020 |
Why?
|
| Mitoguazone | 1 | 1992 | 1 | 0.020 |
Why?
|
| Eflornithine | 1 | 1992 | 2 | 0.020 |
Why?
|
| Ornithine Decarboxylase Inhibitors | 1 | 1992 | 7 | 0.020 |
Why?
|
| Uterus | 2 | 2005 | 39 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 1992 | 247 | 0.020 |
Why?
|
| Heart | 2 | 1985 | 274 | 0.020 |
Why?
|
| Polyamines | 1 | 1992 | 11 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2014 | 202 | 0.020 |
Why?
|
| Technology Assessment, Biomedical | 1 | 1991 | 11 | 0.020 |
Why?
|
| Integrin alpha4beta1 | 1 | 2011 | 2 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 490 | 0.020 |
Why?
|
| L-Selectin | 1 | 2011 | 14 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 16 | 0.020 |
Why?
|
| Receptors, LDL | 1 | 2011 | 33 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2011 | 53 | 0.020 |
Why?
|
| Somatostatin | 1 | 1991 | 18 | 0.020 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2011 | 13 | 0.020 |
Why?
|
| San Francisco | 2 | 2001 | 10 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 2011 | 41 | 0.020 |
Why?
|
| Kidney | 1 | 2014 | 414 | 0.020 |
Why?
|
| Axillary Artery | 2 | 2003 | 7 | 0.020 |
Why?
|
| Pneumonia | 1 | 2014 | 281 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 243 | 0.020 |
Why?
|
| Xerostomia | 1 | 1990 | 9 | 0.020 |
Why?
|
| Eating | 1 | 1991 | 130 | 0.020 |
Why?
|
| Antibodies | 1 | 2011 | 179 | 0.020 |
Why?
|
| Abdominal Neoplasms | 1 | 1990 | 17 | 0.020 |
Why?
|
| Capillary Permeability | 1 | 1990 | 15 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1990 | 148 | 0.020 |
Why?
|
| Cholesterol | 1 | 2011 | 252 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2014 | 330 | 0.020 |
Why?
|
| Intestinal Obstruction | 1 | 1990 | 49 | 0.020 |
Why?
|
| Mitochondria | 1 | 2013 | 343 | 0.020 |
Why?
|
| Leukocytes | 1 | 1990 | 97 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 515 | 0.020 |
Why?
|
| Smoking | 1 | 2015 | 826 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 140 | 0.020 |
Why?
|
| Inguinal Canal | 1 | 2009 | 5 | 0.020 |
Why?
|
| Pelvis | 1 | 1989 | 57 | 0.020 |
Why?
|
| Vomiting | 1 | 1990 | 133 | 0.020 |
Why?
|
| Hemorrhage | 1 | 1991 | 260 | 0.020 |
Why?
|
| Florida | 1 | 2009 | 42 | 0.020 |
Why?
|
| Adolescent | 4 | 1998 | 5835 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 167 | 0.020 |
Why?
|
| New York | 1 | 2009 | 134 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2378 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1990 | 450 | 0.020 |
Why?
|
| Cost Savings | 1 | 2009 | 53 | 0.020 |
Why?
|
| Graft Survival | 1 | 2009 | 290 | 0.020 |
Why?
|
| Palliative Care | 1 | 1990 | 214 | 0.020 |
Why?
|
| Lung | 1 | 2013 | 919 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 241 | 0.020 |
Why?
|
| Radionuclide Imaging | 2 | 1985 | 121 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2009 | 215 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 1991 | 399 | 0.020 |
Why?
|
| Cause of Death | 1 | 2008 | 210 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 1990 | 283 | 0.020 |
Why?
|
| Pain | 1 | 1990 | 396 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 1998 | 1283 | 0.020 |
Why?
|
| Heart Rate | 2 | 1995 | 307 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 1990 | 627 | 0.020 |
Why?
|
| Receptor, Notch4 | 1 | 2005 | 4 | 0.020 |
Why?
|
| Ephrin-B2 | 1 | 2005 | 4 | 0.020 |
Why?
|
| Tetracycline | 1 | 2005 | 22 | 0.020 |
Why?
|
| Vasculitis | 1 | 2005 | 50 | 0.020 |
Why?
|
| Radioisotopes | 1 | 1985 | 23 | 0.010 |
Why?
|
| Fluorescence | 1 | 2005 | 83 | 0.010 |
Why?
|
| Receptors, Notch | 1 | 2005 | 101 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 1985 | 85 | 0.010 |
Why?
|
| Austria | 1 | 2004 | 7 | 0.010 |
Why?
|
| Switzerland | 1 | 2004 | 14 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 1984 | 48 | 0.010 |
Why?
|
| Germany | 1 | 2004 | 52 | 0.010 |
Why?
|
| Europe | 1 | 2004 | 184 | 0.010 |
Why?
|
| Thyroid Function Tests | 1 | 2003 | 13 | 0.010 |
Why?
|
| Age Factors | 1 | 2007 | 1504 | 0.010 |
Why?
|
| Subclavian Artery | 1 | 2003 | 24 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 2003 | 131 | 0.010 |
Why?
|
| Child | 2 | 1995 | 4186 | 0.010 |
Why?
|
| Echocardiography | 1 | 2005 | 457 | 0.010 |
Why?
|
| Thrombin | 1 | 2002 | 21 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 589 | 0.010 |
Why?
|
| Physical Education and Training | 1 | 1982 | 29 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 718 | 0.010 |
Why?
|
| Physical Exertion | 1 | 1982 | 79 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 1982 | 81 | 0.010 |
Why?
|
| RNA, Bacterial | 1 | 2001 | 68 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 2 | 1998 | 735 | 0.010 |
Why?
|
| Electrocardiography | 1 | 1984 | 521 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 795 | 0.010 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2000 | 1 | 0.010 |
Why?
|
| Carotid Body Tumor | 1 | 2000 | 2 | 0.010 |
Why?
|
| Glomus Jugulare Tumor | 1 | 2000 | 3 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2003 | 1051 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 2001 | 259 | 0.010 |
Why?
|
| Mesenteric Artery, Inferior | 1 | 1999 | 4 | 0.010 |
Why?
|
| Takayasu Arteritis | 1 | 1999 | 4 | 0.010 |
Why?
|
| Carotid Artery, Common | 1 | 1999 | 30 | 0.010 |
Why?
|
| Maternal Age | 1 | 1998 | 32 | 0.010 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1998 | 34 | 0.010 |
Why?
|
| Anxiety | 1 | 1982 | 387 | 0.010 |
Why?
|
| Abdominal Abscess | 1 | 1998 | 12 | 0.010 |
Why?
|
| Life Tables | 1 | 1998 | 23 | 0.010 |
Why?
|
| Artifacts | 1 | 1998 | 125 | 0.010 |
Why?
|
| Drainage | 1 | 1998 | 149 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 1998 | 181 | 0.010 |
Why?
|
| Neomycin | 1 | 1996 | 6 | 0.010 |
Why?
|
| Mitral Valve Stenosis | 1 | 1977 | 12 | 0.010 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 1977 | 34 | 0.010 |
Why?
|
| Pneumothorax | 1 | 1977 | 49 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 1996 | 90 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1996 | 95 | 0.010 |
Why?
|
| Pulmonary Emphysema | 1 | 1977 | 99 | 0.010 |
Why?
|
| Arteritis | 1 | 1995 | 4 | 0.010 |
Why?
|
| Replantation | 1 | 1995 | 9 | 0.010 |
Why?
|
| Observer Variation | 1 | 1995 | 205 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1995 | 66 | 0.010 |
Why?
|
| Fibrosis | 1 | 1995 | 153 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 1995 | 137 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1992 | 52 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1995 | 1091 | 0.010 |
Why?
|
| Retinal Vessels | 1 | 1991 | 18 | 0.010 |
Why?
|
| Carotid Artery, Internal | 1 | 1991 | 66 | 0.010 |
Why?
|
| Research Design | 1 | 1994 | 555 | 0.010 |
Why?
|
| Ischemic Attack, Transient | 1 | 1991 | 90 | 0.010 |
Why?
|
| Butylscopolammonium Bromide | 1 | 1990 | 2 | 0.010 |
Why?
|
| Haloperidol | 1 | 1990 | 15 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1992 | 137 | 0.010 |
Why?
|
| Pseudomonas | 1 | 1990 | 7 | 0.010 |
Why?
|
| Streptococcus | 1 | 1990 | 17 | 0.010 |
Why?
|
| Staphylococcus | 1 | 1990 | 16 | 0.010 |
Why?
|
| Morphine | 1 | 1990 | 51 | 0.010 |
Why?
|
| Infant | 1 | 1995 | 1491 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1990 | 285 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1995 | 1792 | 0.010 |
Why?
|
| Terminal Care | 1 | 1990 | 96 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 1989 | 36 | 0.000 |
Why?
|
| Staphylococcus aureus | 1 | 1990 | 169 | 0.000 |
Why?
|
| Endoscopy | 1 | 1989 | 98 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1992 | 1952 | 0.000 |
Why?
|
| Diastole | 1 | 1984 | 89 | 0.000 |
Why?
|
| Hospitalization | 1 | 1990 | 1291 | 0.000 |
Why?
|
| Coronary Artery Bypass | 1 | 1984 | 275 | 0.000 |
Why?
|